Alzheimer's Disease
Cognitive scores may identify incident Alzheimer’s disease
Cognitive tests are effective in predicting incident Alzheimer’s disease in patients with subjective cognitive decline or mild cognitive impairment, according to a poster presentation at the Alzheimer’s Association International Conference.
Alzheimer’s Disease-Health Index reliable tool to measure patient-reported disease burden
The Alzheimer’s Disease-Health Index is a reliable tool for individuals to self-report changes in symptoms or response to therapy, according to research presented at the Alzheimer’s Association International Conference.
Certain cancer survivors far more likely to die of noncancer-related causes
Long-term survivors of certain early-stage cancers diagnosed after age 65 years appeared at higher risk for mortality due to noncancer causes, according to study results published in JAMA Network Open.
Alzheimer’s Association honors researchers for notable contributions in AD, dementia
Seven researchers were honored at the Alzheimer’s Association International Conference for their expertise, contributions and achievements in advancing the field of Alzheimer’s and dementia science, according to an association release.
Prothena to receive $55M from Bristol Myers Squibb for rights to anti-tau antibody
Prothena Corporation plc announced Bristol Myers Squibb exercised its option under its global neuroscience research and development collaboration to obtain exclusive worldwide commercial rights for PRX005, paying Prothena $55 million.
Quanterix launches blood test to detect early Alzheimer’s disease
Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.
False memories not associated with delusions in patients with Alzheimer’s
False memories are not associated with delusions in patients with Alzheimer’s disease, according to a study published in JAMA Psychiatry.
FDA approves Leqembi for Alzheimer’s disease
The FDA has granted Eisai full approval for Leqembi to treat adults with Alzheimer’s disease.
Dementia: Diagnosis and management in the primary care setting
A 73-year-old woman presents with her daughter, who lives down the street from her, and her husband of 51 years for her annual Medicare wellness visit. She has been a patient in the practice for the past 7 to 8 years. She is a retired teacher.
FDA grants 510(k) clearance for CSF assays to aid early Alzheimer’s diagnosis
The FDA has granted 510(k) clearance to Roche for its Elecsys beta-amyloid CSF II and total-tau CSF assays, designed to aid in the diagnosis of adults aged 55 and older being evaluated for Alzheimer’s disease.